RNDP-001 vs TED-A9 (A9-DPC)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopaminergic neuron replacement · full Parkinson's Disease pipeline
RNDP-001
Developed by Kenai Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07106021 (registry estimate)
No aligned efficacy figure on record for this race.
TED-A9 (A9-DPC)
Developed by S.Biomedics
NCT05887466 · Phase 1/2 · completed
The study assigned six participants to each of two dose groups without randomization, blinding, or a placebo or active comparator. Its primary outcomes focused on adverse events and transplant failure or rejection. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2029 · NCT06477744 (registry estimate)
Reported efficacy
Occurrence of treatment-emergent adverse events (TEAEs) after administration of the IP (Up to 96 Weeks (24 months) after IP administration); Failure or rejection of transplantation (Week 12 (3 months)); Failure or rejection of transplantation (Week 24 (6 months)); Failure or rejection of transplantation (Week 48 (12 months)); Failure or rejection of transplantation (Week 96 (24 months)); Occurrence of bleeding (Week 12 (3 months)); Occurrence of bleeding (Week 24 (6 months)); Occurrence of bleeding (Week 48 (12 months)); Occurrence of bleeding (Week 96 (24 months)); Occurrence of infection (Week 12 (3 months)); Occurrence of infection (Week 24 (6 months)); Occurrence of infection (Week 48 (12 months)); Occurrence of infection (Week 96 (24 months)); Occurrence of adverse event of special interest (AESI)* after administration of the IP (Up to 96 Weeks (24 months) after IP administration): Primary endpoint (occurrence of TEAEs) at the 12-month interim readout: 1 of 12 participants had a mild hemorrhage unrelated to the transplant site; no cell/graft-related adverse events or other neurological abnormalities/side effects reported.
Result source: NCT05887466
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | RNDP-001 | TED-A9 (A9-DPC) |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- RNDP-001
- —Not reported
- TED-A9 (A9-DPC)
- —Not reported
ON time without troublesome dyskinesia, change
- RNDP-001
- —Not reported
- TED-A9 (A9-DPC)
- —Not reported
UPDRS Part III, change
- RNDP-001
- —Not reported
- TED-A9 (A9-DPC)
- —Not reported
MDS-UPDRS Part II, change
- RNDP-001
- —Not reported
- TED-A9 (A9-DPC)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
RNDP-001: no structured comparison results are available for Parkinson's Disease.
TED-A9 (A9-DPC): no structured comparison results are available for Parkinson's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: RNDP-001's landscape · TED-A9 (A9-DPC)'s landscape